Cargando…

Modelling prognostic factors in advanced pancreatic cancer

Pancreatic cancer is the fifth most common cause of cancer death. Identification of defined patient groups based on a prognostic index may improve the prediction of survival and selection of therapy. Many prognostic factors have been identified often based on retrospective, underpowered studies with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stocken, D D, Hassan, A B, Altman, D G, Billingham, L J, Bramhall, S R, Johnson, P J, Freemantle, N
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2008
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538756/ https://www.ncbi.nlm.nih.gov/pubmed/19238630 http://dx.doi.org/10.1038/sj.bjc.6604568

Ejemplares similares

Choice of transformation for modelling non-linear continuous biomarkers
por: Stocken, Deborah D, et al.
Publicado: (2011)

A phase II irinotecan–cisplatin combination in advanced pancreatic cancer
por: Markham, C, et al.
Publicado: (2003)

Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer
por: Stocken, D D, et al.
Publicado: (2005)

CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials
por: Maisey, N R, et al.
Publicado: (2005)

Challenges in the development of prognostic models utilising clinical trials data
por: Snell, Kym, et al.
Publicado: (2013)

A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer
por: Bramhall, S R, et al.
Publicado: (2002)

Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials
por: Neoptolemos, J P, et al.
Publicado: (2009)

Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP)
por: Vernerey, Dewi, et al.
Publicado: (2016)

Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer
por: Fornaro, L, et al.
Publicado: (2014)

Flexible modeling improves assessment of prognostic value of C-reactive protein in advanced non-small cell lung cancer
por: Gagnon, B, et al.
Publicado: (2010)

Prognostic factors and sites of metastasis in unresectable locally advanced pancreatic cancer
por: Peixoto, Renata D’Alpino, et al.
Publicado: (2015)

Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy
por: Sultana, A, et al.
Publicado: (2007)

A phase II study of raltitrexed and gemcitabine in patients with advanced pancreatic carcinoma
por: Arends, J J, et al.
Publicado: (2005)

Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer
por: Hussain, S A, et al.
Publicado: (2004)

Prognostic nomogram for nonresectable pancreatic cancer treated with gemcitabine-based chemotherapy
por: Hamada, T, et al.
Publicado: (2014)

Gemcitabine with a specific conformal 3D 5FU radiochemotherapy technique is safe and effective in the definitive management of locally advanced pancreatic cancer
por: Goldstein, D, et al.
Publicado: (2007)

A phase I trial of Capecitabine+Gemcitabine with radical radiation for locally advanced pancreatic cancer
por: Michael, M, et al.
Publicado: (2009)

Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer
por: Graeven, U, et al.
Publicado: (2006)

FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience
por: Chllamma, Muralidharan K, et al.
Publicado: (2016)

Confirmed Angiosarcoma: Prognostic Factors and Outcome in 50 Prospectively Followed Patients
por: Espat, N. J., et al.
Publicado: (2000)

Pancreatic Resections for Advanced M1-Pancreatic Carcinoma: The Value of Synchronous Metastasectomy
por: Seelig, S. K., et al.
Publicado: (2010)

Estimating prognosis and palliation based on tumour marker CA 19-9 and quality of life indicators in patients with advanced pancreatic cancer receiving chemotherapy
por: Bernhard, J, et al.
Publicado: (2010)

Baseline tumour measurements predict survival in advanced non-small cell lung cancer
por: Gerber, D E, et al.
Publicado: (2013)

A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer
por: Hussain, S A, et al.
Publicado: (2004)

ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomised, phase II trial
por: Bauman, J E, et al.
Publicado: (2013)

External validation of three prognostic models for overall survival in patients with advanced-stage epithelial ovarian cancer
por: van de Laar, R, et al.
Publicado: (2014)

A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer
por: Yoo, C, et al.
Publicado: (2009)

Assessment of Nutritional Status, Digestion and Absorption, and Quality of Life in Patients with Locally Advanced Pancreatic Cancer
por: Witvliet-van Nierop, J. E., et al.
Publicado: (2017)

Prognostic/predictive value of 207 serum factors in colorectal cancer treated with cediranib and/or chemotherapy
por: Spencer, S K M, et al.
Publicado: (2013)

Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials
por: Chau, I, et al.
Publicado: (2006)

Weekly full-dose gemcitabine and single-dose cisplatin with concurrent radiotherapy in patients with locally advanced pancreatic cancer
por: Hong, S P, et al.
Publicado: (2008)

Prognostic Factors and Metastatic Patterns in Primary Myxoid/Round-Cell Liposarcoma
por: Haniball, J., et al.
Publicado: (2011)

Management of febrile neutropenia in the United Kingdom: time for a national trial?
por: Innes, H, et al.
Publicado: (2005)

Identifying patients with undetected colorectal cancer: an independent validation of QCancer (Colorectal)
por: Collins, G S, et al.
Publicado: (2012)

Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers
por: Golan, T, et al.
Publicado: (2014)

Prognostic significance of L-type amino-acid transporter 1 expression in surgically resected pancreatic cancer
por: Kaira, K, et al.
Publicado: (2012)

Metastatic melanoma: prognostic factors and survival in patients with brain metastases
por: Frinton, E., et al.
Publicado: (2017)

A phase I trial of S-1 with concurrent radiotherapy for locally advanced pancreatic cancer
por: Ikeda, M, et al.
Publicado: (2007)

Locally Advanced Pancreatic Head Cancer: Margin-Positive Resection or Bypass?
por: Wellner, Ulrich Friedrich, et al.
Publicado: (2012)

Phase I/II study of verteporfin photodynamic therapy in locally advanced pancreatic cancer
por: Huggett, M T, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_fa9duumd8mo9tr78ahqk3as1qh